Dr. Julie Holland is a psychiatrist and psychopharmacologist, and author of the New York Times bestseller Moody Bitches and Weekends at Bellevue. She is the editor of two non-profit books: Ecstasy: The Complete Guide and The Pot Book: A Complete Guide to Cannabis. While now a medical advisor to MAPS, she was a medical monitor for several clinical studies examining the efficacy of using MDMA-assisted psychotherapy or cannabis in the treatment of Post Traumatic Stress Disorder. Her newest book is Good Chemistry: The Science of Connection, From Soul to Psychedelics.
PsyTech is excited to announce its upcoming PsyTech Summit 2020, taking place on October 27th. This will be a one-day, international event bringing together decision makers, investors, clinicians, thought leaders, and advocates for the purpose of advancing psychedelics science, business, and reform. The Summit will cater to thousands of virtual attendees as well as live guests at select city hubs across four continents.
For our upcoming Summit, PsyTech’s vision is a spirited high-level global discussion that integrates decades of psychedelics science, medicinal scholarship, and exciting emerging innovations with a growing number of professionals interested in the sector.
Professor David Nutt
David Nutt is a psychiatrist and the Edmond J. Safra Professor of Neuropsychopharmacology in the Division of Brain Science, Dept of Medicine, Hammersmith Hospital, Imperial College London. His research area is psychopharmacology – the study of the effects of drugs on the brain, from the perspectives of both how drug treatments in psychiatry and neurology work, and why people use and become addicted to some drugs such as alcohol. To study the effects of drugs in the brain he uses state of the art techniques such as brain imaging with PET and fMRI plus EEG and MEG. This research output has led to over 500 original research papers and a similar number of reviews and books chapters, eight government reports on drugs and 35 books, including one for the general public, Drugs: without the hot air, that won the Transmission Prize in 2014.
He was previously President of the European Brain Council, the British Association of Psychopharmacology, the British Neuroscience Association and the European College of Neuropsychopharmacology. He is currently Founding Chair of DrugScience.org.uk and holds visiting Professorships at the Open University and University of Maastricht.
David broadcasts widely to the general public both on radio and television. In 2010 The Times Eureka science magazine voted him one of the 100 most important figures in British Science, and the only psychiatrist in the list. In 2013 he was awarded the John Maddox Prize from Nature/Sense about Science for standing up for science and in 2017 a Doctor of Laws hon causa from the University of Bath
Dr. Bia Labate
Dr. Beatriz Caiuby Labate (Bia Labate) is a queer Brazilian anthropologist who immigrated to the U.S. in 2017. She has a Ph.D. in social anthropology from the State University of Campinas (UNICAMP), Brazil. Her main areas of interest are the study of plant medicines, drug policy, shamanism, ritual, and religion. She is Executive Director of the Chacruna Institute for Psychedelic Plant Medicines (http://chacruna.net), an organization that provides public education about psychedelic plant medicines. She is Adjunct Faculty at the East-West Psychology Program at the California Institute of Integral Studies (CIIS) in San Francisco. She is also Public Education and Culture Specialist at the Multidisciplinary Association for Psychedelic Studies (MAPS). She is co-founder of the Interdisciplinary Group for Psychoactive Studies (NEIP) in Brazil, and editor of NEIP’s website (http://www.neip.info), as well as editor of the Mexican blog Chacruna Lationamérica (http://drogaspoliticacultura.net). She is author, co-author, and co-editor of twenty-one books, two special-edition journals, and several peer-reviewed articles (http://bialabate.net)
Rick Doblin, Ph.D., is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS). He received his doctorate in Public Policy from Harvard’s Kennedy School of Government, where he wrote his dissertation on the regulation of the medical uses of psychedelics and marijuana and his Master’s thesis on a survey of oncologists about smoked marijuana vs. the oral THC pill in nausea control for cancer patients. His undergraduate thesis at New College of Florida was a 25-year follow-up to the classic Good Friday Experiment, which evaluated the potential of psychedelic drugs to catalyze religious experiences. He also conducted a thirty-four year follow-up study to Timothy Leary’s Concord Prison Experiment. Rick studied with Dr. Stanislav Grof and was among the first to be certified as a Holotropic Breathwork practitioner. His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people, and eventually to become a legally licensed psychedelic therapist. He founded MAPS in 1986, and currently resides in Boston with his wife, dog, and empty rooms from three children, one of whom is in college and two have graduated.
Keren Tzarfaty, Ph.D.
Keren Tzarfaty, Ph.D. is the co-founder of the Hakomi Institute of Israel a trainer for MAPS in Israel (Multidisciplinary Association for Psychedelic Studies). She is a clinical investigator in the MDMA PTSD FDA approved clinical trial, examining the impact of MDMA assisted psychotherapy on severe PTSD patients.
Professor Mathew Johnson
Matthew W. Johnson, Ph.D., is Professor of Psychiatry and Behavioral Sciences at Johns Hopkins. He is one of the world’s most published scientists on the human effects of psychedelics. Matt earned his Ph.D. in experimental psychology at the University of Vermont in 2004, and has published >110 peer-reviewed articles. Working with psychedelics for 16 years, Matt published psychedelic safety guidelines in 2008, helping to resurrect psychedelic research. As Principle Investigator he developed and published the first research on psychedelic treatment of tobacco addiction in 2014. Matt and colleagues published the largest study of psilocybin in treating cancer distress in 2016. His 2018 psilocybin abuse liability review recommended placement in Schedule-IV upon potential medical approval. He is Principle Investigator on funded studies investigating psilocybin in the treatment of opioid dependence and PTSD. Matt is also known for his behavioral economics research, including decision-making underlying addiction, tobacco regulatory science, and drug effects on sexual risk behavior. He has published studies on nearly all psychoactive drug classes. Matt was 2019 President of the Psychopharmacology and Substance Abuse Division of the American Psychological Association, and is current
President of the International Society for Research on Psychedelics. He has received continuous NIH funding as Principal Investigator for > 12 years. He has reviewed for >75 journals and has served as guest editor on two special issues on psychedelics. Matt has reviewed grants for NIH, NSF, the US Military, and multiple governments outside of the US. He has provided invited presentations in 13 nations. Matt has been interviewed widely by media including 60 Minutes, New York Times, Washington Post, Wall Street Journal, BBC, CNN, NPR, and Fox Business News. Matt’s research was featured on an episode of Breakthrough produced by Ron Howard on the National Geographic Channel, and in Michael Pollan’s book, How to Change Your Mind. Twitter: @Drug_Researcher
Tomas Páleníček, MD, PhD.
Tomas Páleníček, MD, PhD. began his career in 2001 in preclinical research at the former Prague Psychiatric Centre, focusing on the neurobiology of psychedelics such as LSD, psilocin, mescaline, 2C-B and MDMA and on the neurobiology of psychosis. At the same time, he trained in clinical psychiatry and in clinical electroencephalography (EEG) and began contributing to the human clinical research of ketamine. Within the last five years, he has been the principle investigator in the first projects performed in the Czech Republic to study the acute effects of cannabis and psilocybin in healthy volunteers and has been involved in studies with ketamine in depressed patients. His research expertise is mainly focussed on behavioural pharmacology and electrophysiology and brain connectivity. Currently, he is the leader of a translational team of young scientists at the National Institute of Mental Health in the Czech Republic, investigating the neurobiology of how psychedelics and cannabinoids affect brain processing, emotionality, cognitive functions and music. He is also actively involved in projects studying the therapeutic potential of psychedelics and MDMA in the Czech Republic.
Timothy Ko has a broad background of leading private ventures in the Service Sector, Investor Relations, Retail and Technology. Most recently he served as Director of Hyperbridge Technology, a company focused on the development of decentralized technologies that facilitate crowdfunding.
Timothy’s passion for the psychedelic space is shaped by firsthand knowledge of the shortcomings of the current mental health and substance-use treatment models, and through his exposure to psychedelics, which he credits with saving his life. Following the loss of a loved one to a decades’ long fight with mental health and addictions, and through his personal experiences, Timothy is driven to develop and provide access to the life saving potential of psychedelic medicines.
Madison Margolin is Co-Founder and Managing Editor of DoubleBlind. Having written for Playboy Magazine, Rolling Stone, Nylon, VICE, LA Weekly, High Times, Tablet, and other outlets, her reporting is concentrated on psychedelics, cannabis, drug policy, and spirituality. A graduate of Columbia Journalism School and UC Berkeley, Madison has traveled everywhere from pot farms in the Emerald Triangle to the shores of the Ganges River, and all over Israel-Palestine, exploring the role of entheogens in religion, mental health, and conflict resolution. With more than five years’ experience covering both drugs and Jewish culture, she got her start in journalism with a column on cannabis at the Village Voice, after having lived in south Tel Aviv working with nonprofits that serve Eritrean refugees and LGBTQI+ asylum-seekers.
Dr. Robin Carhart-Harris
Dr Robin Carhart-Harris moved to Imperial College London in 2008 after obtaining a PhD in Psychopharmacology from the University of Bristol and an MA in Psychoanalysis from Brunel University. At Imperial, Robin has designed human brain imaging studies with LSD, psilocybin, MDMA and DMT, a clinical trial of psilocybin for treatment-resistant depression, an ongoing trial comparing psilocybin with escitalopram for major depressive disorder and a multimodal imaging study in healthy volunteers receiving psilocybin for the first time. Robin founded the Centre for Psychedelic Research at Imperial College London in April 2019, the first of its kind in the world.
Tania De Jong
Tania de Jong AM is one of Australia’s most successful female entrepreneurs and innovators having developed 5 businesses and 3 charities over 3 decades. Tania works across the public, private, creative and social sectors. She founded Creativity Australia, Creative Universe, MTA Entertainment & Events and The Song Room and works with disadvantaged communities through Creativity Australia’s ‘With One Voice’ choir social inclusion programs. She has recently co-founded Mind Medicine Australia whose objective is for psychedelic-assisted psychotherapies to play a major role in improving the treatments available for Australians suffering from mental illness.
Tania presents keynote speeches and leadership programs and performs internationally as a soloist and with her group Pot-Pourri. She has released twelve albums including her new solo releases Flying Free, Solitary Harmony and The Breezes at Dawn have Secrets to Tell.
Tania’s TED Talk ‘How Singing Together Changes The Brain’ has sparked international interest.
She is Founder and Executive Producer of Creative Innovation Global winning national and international awards. Creative Universe and Creative Innovation Global were ranked among the top 20 event organizers and agencies from around the world as part of the Eventex All-Stars Index.
Tania has founded a co-working space called Dimension5 in Melbourne to drive social innovation and collaboration.
Tania’s awards include Ernst and Young Australian Social Entrepreneur of the Year. She was inducted into the AGSE Entrepreneurs Hall of Fame at Swinburne University and named Brainlink Woman of Achievement. Tania was named in the 100 Women of Influence and the 100 Australian Most Influential Entrepreneurs and recently was honoured with the Award for Meritorious Service to the Community in the Victorian Multicultural Awards for Excellence 2019.
She was appointed a Member of the Order of Australia in June 2008 for service to the Arts as a performer and entrepreneur and through the establishment and development of music and arts enrichment programs for schools and communities.
Tania’s mission is to change the world, one voice at a time!
Dr. Adele Lafrance
Dr. Adele Lafrance is a clinical psychologist, research scientist, and certified eating disorder specialist and supervisor. She is a leader in the research and practice of psychedelic medicine in the context of eating disorders, with a focus on ayahuasca, MDMA, and psilocybin. Currently, Dr. Lafrance is the clinical investigator and strategy lead for the MAPS-sponsored MDMA-assisted psychotherapy study for eating disorders, and a collaborator on the Imperial College study for psilocybin and anorexia nervosa. She is also co-developer of Emotion-Focused Ketamine-assisted Psychotherapy and Emotion-Focused Family Therapy for Eating Disorders. Dr. Lafrance has a particular interest in mechanisms and models of healing, including spirituality, emotion processing, and the application of psychedelic medicine in the context of couples and family therapy. A frequent speaker at professional conferences, She has published extensively in the field of emotion and health, including a clinical manual and expert training video published by the American Psychological Association.
Dr. Andrew Hegle
Dr. Andrew Hegle has been an adjunct professor of Pharmacology at the University of British Columbia since 2015. With a background in molecular biology and biochemistry, Dr. Hegle has published research investigating the role of membrane receptor proteins in physiology, behavior and disease.
Dr. Hegle’s main professional focus has been in the creation and management of laboratory operations; has held executive and operational management positions at several biotechnology companies; and was a co-founder of both Cannevert Therapeutics and Canalytic Laboratories in Vancouver, BC. Dr Hegle has a long-held interest in the therapeutic potential of psychedelic medicine and is delighted to commit himself to furthering this field.
Dr. Reid Robison, MD
Reid Robison, MD MBA, is a board-certified psychiatrist who has led over 100 clinical trials in neuropsychiatry. Reid is co-founder at Cedar Psychiatry, and serves as Medical Director of Center for Change, a top Eating Disorder program. He is currently the coordinating investigator for the MAPS MDMA-assisted Psychotherapy study of Eating Disorders. As an early adopter and researcher of Ketamine in psychiatry, Reid obtained his first grant to study ketamine in 2011. He also led the Utah site for the pivotal ketamine study for TRMDD by Janssen, leading up to the company’s recent FDA-approval of Spravato. To date, Reid has guided thousands of ketamine therapy journeys and hundreds of Spravato dosing sessions. As a social entrepreneur, Reid has built a number of purpose-driven companies including Tute Genomics, a venture-backed personalized medicine startup that was acquired in 2016. Reid is adjunct faculty at the University of Utah, founder of the Polizzi Free Clinic, and provides medical support and psychedelic therapy at plant medicine retreats abroad.
Shelby Hartman is the co-founder and editor-in-chief of DoubleBlind, a biannual print magazine and digital media company at the forefront of the rapidly growing psychedelic movement. Also a reporter and editor specializing in psychedelics, cannabis, drug policy, and mental health, her work has appeared in VICE, Quartz, the Huffington Post, and Rolling Stone, among others. Hartman worked in broadcast news production for CBS News, covering presidential elections, protests, natural disasters, and other breaking news. Spurred by a passion for print and investigative reporting, she transitioned to magazine writing, working as an editor at Pasadena Magazine and receiving her Master’s Degree in long-form journalism from Columbia University in 2015. Since, Hartman has worked as a columnist at LA Weekly and an editor at Herb, the largest cannabis media company, with extensive features on the cannabis industry, the psychedelic research boom, the popularization of ayahuasca, and post-traumatic stress disorder in the veteran community.
Del comes from a position leading business development for Charlotte’s Web Hemp oil, one of the world’s largest CBD oil producer. Del is currently on the community board of advisors to the Realm of caring, a high impact cannabis non-profit, and was the outreach director to the Decriminalize Denver campaign, which passed a historical initiative to decriminalize psilocybin in the city of Denver.
our international hosts
This year’s Summit will cater to thousands of virtual attendees as well as a smaller group of live guests hosted by our international hubs, which will be live streaming from their host cities. We are excited to launch a cutting edge event that integrates Covid-safe yet intimate in-person networking alongside a virtual summit reaching thousands across the global psychedelic community.
Help us drive forward psychedelic research, education, and innovation by donating to these organizations so they can continue their important work.